Nachrichten und Videos - RIGEL PHARMACEUTICALS INC. - Seite 2

Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close on Tuesday, November 7 , 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30...

Rigel Announces Presentation at the Upcoming IDWeek 2023 PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 -- Provides Update on ACTIV-4 Host Tissue Trial -- SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors at...

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 6, 2023 SOUTH SAN FRANCISCO, Calif. , Oct. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ...

Rigel to Present at the 2023 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 20, 2023 SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 3:35 p.m. ET in New York, NY . To access the live webcast or archived recording, visit...

Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, and Dean Schorno , the company's chief financial officer, will participate in the following investor conferences in September: 2023 Wells Fargo Healthcare Conference, September 6-8, 2023...

Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 1, 2023 Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE ® net product sales of $21.3 million and REZLIDHIA ® net product sales of $2.6 million Development programs continue to advance with completion of target enrollment in cohort 2 of Phase 1b trial of R289 in lower-risk MDS and initiation of Phase 2a trial of R552 in rheumatoid arthritis...

Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., July 25, 2023 SOUTH SAN FRANCISCO, Calif. , July 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close on Tuesday, August 1 , 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30...

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., July 5, 2023 SOUTH SAN FRANCISCO, Calif. , July 5, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into...

Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML PR Newswire SOUTH SAN FRANCISCO, Calif., June 7, 2023 Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress SOUTH SAN FRANCISCO, Calif. , June 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today...

Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances PR Newswire SOUTH SAN FRANCISCO, Calif., June 6, 2023 Review article examines the preclinical and clinical development, and the role of olutasidenib in the m IDH1 AML treatment landscape. Authors conclude, "The approval of olutasidenib is a critical addition to the m IDH1 AML treatment landscape with encouragingly durable responses." SOUTH SAN FRANCISCO, Calif. , June 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals,...

Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting PR Newswire SOUTH SAN FRANCISCO, Calif., June 1, 2023 SOUTH SAN FRANCISCO, Calif. , June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023 , in Chicago, IL , and virtually. Rigel...

Rigel to Present at the Jefferies 2023 Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., May 31, 2023 SOUTH SAN FRANCISCO, Calif. , May 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, will present on Wednesday, June 7, 2023 at 2:30 p.m. ET at the Jefferies 2023 Global Healthcare Conference, being held June 7-9, 2023 in New York, NY . To access the live and subsequent...

Rigel Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., May 2, 2023 First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE ® net product sales of $22.3 million and REZLIDHIA ® net product sales of $1.5 million Global expansion of TAVALISSE in ITP with Japanese launch by partner Kissei Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. , May 2, 2023 /PRNewswire/ --...

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., April 25, 2023 SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close on Tuesday, May 2 , 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m....

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., April 6, 2023 SOUTH SAN FRANCISCO, Calif. , April 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into...

Thinking about buying stock in Rigel Pharmaceuticals, Maxeon Solar Technologies, Kimball International, Diversey Holdings, or Fresh Tracks Therapeutics? PR Newswire NEW YORK, March 8, 2023 NEW YORK , March 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIGL, MAXN, KBAL, DSEY, and FRTX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. RIGL:...

Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., March 7, 2023 Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA ™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch continues to progress and is supported by recent addition to NCCN Guidelines ® for AML Conference call and webcast scheduled today at 4:30 p.m....

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023 . Rigel senior management will follow the announcement with a live conference...

Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 2, 2023 ˗ REZLIDHIA induced durable remissions in adult patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication of data in Blood Advances , which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™...

National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 SOUTH SAN FRANCISCO, Calif. , Jan. 18, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA ™ (olutasidenib) has been added by the National Comprehensive Cancer Network ® (NCCN ® ) to the latest NCCN Clinical Practice Guidelines in Oncology...